Shares of AbbVie Inc. ABBV advanced 1.88% to $180.37 Thursday, on what proved to be an all-around favorable trading session ...

Cantor Fitzgerald analyst Carter Gould initiated coverage of AbbVie (ABBV) with an Overweight rating and $210 price target AbbVie offers a “compelling mix of growth and defense” with a ...

Scotiabank analyst Louise Chen initiated coverage with a Buy rating on AbbVie (ABBV – Research Report) yesterday and set a price target of $210.00. The company’s shares closed yesterday at ...

AbbVie has reported new phase 3 data for its schizophrenia and bipolar disorder therapy Vraylar in treatment-resistant depression, as it waits for a decision by the FDA on the new indication.

AbbVie (NYSE:ABBV) is scheduled to announce its earnings on Friday, April 25, 2025. Currently, the company holds a market capitalization of $307 billion. Over the past twelve months, AbbVie ...

A report by the Senate Finance Committee has concluded that AbbVie exploited a financial loophole introduced by former President Donald Trump in 2017 to avoid paying "billions in taxes." The ...

It's been a stomach-churning past few months for investors in pharmaceutical giant AbbVie (NYSE: ABBV). A potential blockbuster drug that AbbVie spent roughly $9 billion to acquire the rights to ...

AbbVie Price Performance NYSE ABBV opened at $173.72 on Wednesday. The firm has a market cap of $307.31 billion, a P/E ratio of 72.38, a price-to-earnings-growth ratio of 1.62 and a beta of 0.55 ...

Carrie Strom, the top official at AbbVie’s Allergan Aesthetics, recently announced her departure from the AbbVie-owned company. Since 2020, Strom has led the Irvine-based aesthetics unit of AbbVie, ...

In the latest market close, AbbVie (ABBV) reached $170.16, with a -1.64% movement compared to the previous day. The stock exceeded the S&P 500, which registered a loss of 2.36% for the day.